IPM Take
Cardiology’s AI debate is too often reduced to a competition over accuracy. That misses the real policy problem.
An algorithm may detect an arrhythmia, estimate future heart failure risk or identify an abnormality in an image. But it cannot decide who contacts the patient, who confirms the result, who pays for additional testing, who is accountable when the model fails, or whether it performs equally well across different populations.
Cardiology does not need more black boxes dropped into fragmented pathways. It needs evidence that AI changes care, improves outcomes and does not quietly automate existing inequalities.
Executive Summary
A narrative review published in Cureus examines artificial intelligence applications across cardiovascular diagnosis and risk prediction. It covers AI-supported ECG interpretation, cardiovascular imaging, arrhythmia monitoring, heart failure assessment, digital health and wearable technologies. The authors conclude that AI may support earlier diagnosis, risk stratification and more personalised care.
The review also identifies the barriers standing between promising models and routine medicine: limited dataset diversity, weak generalisability, retrospective development, inadequate external validation, poor interpretability, privacy concerns and difficult integration into clinical workflows. Importantly, this was a narrative review rather than a systematic review or meta-analysis. It maps the field, but it does not prove that AI improves cardiovascular outcomes.
That distinction matters. The American Heart Association has similarly warned that, although cardiovascular AI tools are promising, few have achieved widespread clinical adoption and evidence that they improve care remains limited. Meanwhile, regulators are constructing rules for AI-enabled medical devices, but health systems still lack consistent standards for procurement, reimbursement, human oversight and post-deployment monitoring.
Why it matters
- Policymakers and regulators: Approval should not be the endpoint. Cardiovascular AI requires lifecycle monitoring, transparency, bias assessment and clear accountability when performance changes after deployment.
- HTA bodies and payers: Model accuracy alone is not enough. Assessment should examine clinical utility, patient outcomes, workflow burden, cost-effectiveness and whether an actionable care pathway exists.
- Clinicians and hospitals: Every automated alert creates a potential clinical obligation. Providers need defined responsibility for reviewing results, confirming diagnoses and communicating with patients.
- Patients and advocates: Patients should know when AI influences their care, how their data are used and what happens when a model produces an incorrect or uncertain result.
- Industry and AI developers: The market will increasingly demand evidence across diverse populations, independent validation and monitoring after deployment, not another impressive performance metric from a retrospective dataset.
The ECG is recorded before the patient sees a cardiologist.
Within seconds, an algorithm detects a pattern that the human eye might not recognise. It generates a warning: this patient may face an increased risk of heart failure.
Then the difficult part begins.
Does someone call the patient? Is another ECG required? Should an echocardiogram be ordered? Will the payer cover it? How urgently should the result be reviewed? What happens if the model was trained on patients who look very different from the person sitting in the clinic?
The algorithm has completed its task.
The health system has not.
That is the uncomfortable message behind a new peer-reviewed review of artificial intelligence in cardiology. Published in Cureus on 17 July 2026, the paper describes a rapidly expanding field in which machine learning and deep learning are being applied to ECGs, cardiovascular imaging, electronic health records, wearable data and clinical risk prediction.
The potential is real.
AI-supported ECG models have been studied for arrhythmia detection, cardiovascular classification and prediction of future heart failure risk. Imaging algorithms can automate measurements, identify cardiac structures and support interpretation of echocardiography, CT and MRI. Wearables can collect rhythm and physiological data outside the hospital, creating opportunities to identify intermittent abnormalities that may be missed during a short clinical appointment.
In theory, this is personalised cardiovascular medicine at scale.
A patient’s ECG, imaging, laboratory data, medical history and wearable signals could be combined to identify risk earlier and guide more individualised prevention.
But the review also exposes how far implementation remains behind technological ambition.
Many cardiovascular AI models are developed retrospectively using datasets collected at a small number of institutions. A model may perform impressively in the hospital where it was built and deteriorate when introduced elsewhere. Differences in patient demographics, clinical practice, recording equipment and disease prevalence can all affect performance.
This is not a minor technical inconvenience.
It is a patient-safety problem.
A model that performs less accurately in women, older adults, ethnic minorities or people treated in lower-resource settings could reproduce cardiovascular inequality behind a screen of mathematical neutrality. The algorithm may appear objective while its training data encode the blind spots of the health system that produced them.
The review is appropriately cautious. It is a narrative synthesis, not a systematic review or meta-analysis. The included evidence is heterogeneous, and the paper does not provide pooled estimates demonstrating that AI improves survival, prevents hospitalisation or reduces cardiovascular events.
That limitation reflects a wider problem in medical AI.
The field has become very good at reporting discrimination, sensitivity, specificity and area under the curve. It has been less successful at showing what happens after the model enters a real clinic.
An AUC is not a care pathway.
A highly accurate model may still have little value if clinicians do not trust it, patients cannot access confirmatory testing, alerts arrive without clear responsibility, or the intervention triggered by the prediction does not improve outcomes.
False positives also create costs. They can lead to anxiety, additional appointments, imaging and specialist referrals. False negatives can offer reassurance where urgent care was needed. In both cases, responsibility can become blurred between the clinician, hospital, software developer and device manufacturer.
Regulators are beginning to confront the fact that AI-enabled devices are not static products.
The US Food and Drug Administration maintains a public list of authorised AI-enabled medical devices and has issued guidance on predetermined change control plans. These plans are intended to allow specified algorithm updates while maintaining evidence of safety and effectiveness throughout the product lifecycle.
Europe is also building a risk-based framework through the AI Act and existing medical-device legislation. Under the political agreement reached in 2026 on simplifying implementation, the European Commission states that rules for high-risk AI embedded in regulated products are expected to apply from August 2028. That may give manufacturers and regulators more time to prepare standards, but it also leaves health systems managing a fast-moving technology during a prolonged transition.
Regulation alone will not solve the implementation problem.
Payers and HTA bodies must decide what evidence is sufficient to fund an AI tool. Hospitals must determine who reviews its outputs. Clinicians need training in both the capabilities and limitations of models. Patients need understandable explanations of how automated recommendations influence their care.
Procurement decisions also need to become more demanding.
Before purchasing cardiovascular AI, a health system should know how the model performed across relevant demographic groups, whether it has been externally and prospectively validated, how often it produces false alerts, whether clinicians can override it, how updates will be monitored and what happens when its performance drifts.
WHO guidance has emphasised transparency, external validation, data quality, privacy protection, lifecycle documentation and human involvement as core elements of responsible health AI regulation. These are not bureaucratic obstacles to innovation. They are the conditions under which innovation becomes trustworthy medicine.
The reimbursement question may be even more decisive.
It makes little sense to fund an algorithm that identifies high-risk patients without funding the clinicians, tests and services required to respond. A wearable alert without a review pathway is not prevention. It is outsourced uncertainty.
AI could help cardiology move from treating events to identifying risk before irreversible damage occurs. It could support specialists facing rising demand and help extend expertise beyond major cardiovascular centres.
But that future is not guaranteed.
Without careful governance, AI may simply generate more alerts for overstretched clinicians, more data for poorly connected systems and more sophisticated explanations for why vulnerable patients were missed.
The next phase of cardiovascular AI should not be judged by whether a machine can detect a hidden signal.
It should be judged by whether the patient benefits after it does.
